STATEN ISLAND, N.Y. , June 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx Pharmaceuticals, Inc. (Nasdaq:ACXP), highlighted a potentially transformative regulatory...
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity
STATEN ISLAND, N.Y. , April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics...
Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class...
STATEN ISLAND, N.Y. , April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution...
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Three Consecutive Years of Ongoing Predictable Media™ Partnership